Shares of Century Therapeutics, Inc. ( NASDAQ:IPSC – Get Free Report ) have earned a consensus rating of 'Moderate Buy' from the eight research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $15.33. IPSC has been the topic of a number of research analyst reports.

https://www.dailypolitical.com/2023/09/30/brokerages-set-century-therapeutics-inc-nasdaqipsc-target-price-at-15-33.html

#dailypolitical